Characterization of Substrates and Inhibitors for the In Vitro Assessment of Bcrp Mediated Drug–Drug Interactions

PurposeIn vitro assessment of drug candidates' affinity for multi-drug resistance proteins is of crucial importance for the prediction of in vivo pharmacokinetics and drug–drug interactions. To have well described experimental tools at hand, the objective of the study was to characterize substrates and inhibitors of Breast Cancer Resistance Protein (BCRP) and P-glycoprotein (P-gp).MethodsMadin–Darbin canine kidney cells overexpressing mouse Bcrp (MDCKII-Bcrp) were incubated with various Bcrp substrates, or a mixture of substrate and inhibitor to either the apical (A) or basolateral (B) compartment of insert filter plates. Substrate concentrations in both compartments at time points t = 0 h and t = 2 h were determined by LC–MS/MS, and respective permeation coefficients (Papp) and efflux ratios were calculated.ResultsThe Bcrp inhibitor Ko143 blocked topotecan and ABZSO transport in a concentration-dependent manner. P-gp inhibitors ivermectin, LY335979, PSC833, and the P-gp/Bcrp inhibitor ritonavir did not influence Bcrp mediated topotecan transport, however, blocked ABZSO transport. Additionally, neither was ABZSO transport influenced by topotecan, nor topotecan transport by ABZSO.ConclusionsData suggest different modes of substrate and inhibitor binding to Bcrp. In order to not overlook potential drug–drug interactions when testing drug candidates for inhibitory potential towards Bcrp, distinct Bcrp probe substrates should be used.

[1]  E. Georges,et al.  Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. , 1997, Biochemical pharmacology.

[2]  D. Clarke,et al.  Identification of Residues in the Drug-binding Domain of Human P-glycoprotein , 1999, The Journal of Biological Chemistry.

[3]  A. Schinkel,et al.  TRANSPORT OF ANTHELMINTIC BENZIMIDAZOLE DRUGS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) , 2005, Drug Metabolism and Disposition.

[4]  J. Polli,et al.  IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES , 2006, Drug Metabolism and Disposition.

[5]  J. Schellens,et al.  The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. , 2005, Cancer research.

[6]  J. Schuetz,et al.  Role of ABCG2/BCRP in biology and medicine. , 2006, Annual review of pharmacology and toxicology.

[7]  A. Dantzig,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. , 1996, Cancer research.

[8]  L J Lesko,et al.  Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.

[9]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  B. Hirst,et al.  The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  M. Kool,et al.  Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport , 2000, British Journal of Cancer.

[12]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[13]  E. Petzinger,et al.  Drug transporters in pharmacokinetics , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[14]  A. E. Senior,et al.  Projection Structure of P-glycoprotein by Electron Microscopy , 2002, The Journal of Biological Chemistry.

[15]  R. Dawson,et al.  Structure of a bacterial multidrug ABC transporter , 2006, Nature.

[16]  T. Litman,et al.  Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. , 2001, Biochemical and biophysical research communications.

[17]  J. Schellens,et al.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Callaghan,et al.  Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter , 2006, British journal of pharmacology.

[19]  Jörg Huwyler,et al.  Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. , 2003, Journal of medicinal chemistry.

[20]  H. Kakeya,et al.  Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. I. Taxonomy, fermentation, isolation and biological properties. , 1996, The Journal of antibiotics.

[21]  D. Ross,et al.  Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. , 2006, Blood.

[22]  C. Higgins,et al.  Three-dimensional Structure of P-glycoprotein , 2005, Journal of Biological Chemistry.

[23]  C. Higgins,et al.  Communication between multiple drug binding sites on P-glycoprotein. , 2000, Molecular pharmacology.

[24]  V. Ling,et al.  Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. , 2001, European journal of biochemistry.

[25]  J. Schuetz,et al.  Function-dependent Conformational Changes of the ABCG2 Multidrug Transporter Modify Its Interaction with a Monoclonal Antibody on the Cell Surface* , 2005, Journal of Biological Chemistry.

[26]  Yi Zhang,et al.  HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[27]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[29]  Hong-Bin Fang,et al.  Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. , 2003, Molecular pharmacology.

[30]  H. Kakeya,et al.  Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. II. Physico-chemical properties and structures. , 1996, The Journal of antibiotics.

[31]  Thomas J. Raub,et al.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.

[32]  D. Clarke,et al.  Identification of Residues within the Drug-binding Domain of the Human Multidrug Resistance P-glycoprotein by Cysteine-scanning Mutagenesis and Reaction with Dibromobimane* , 2000, The Journal of Biological Chemistry.

[33]  榎園 淳一.  血液組織関門におけるBreast Cancer Resistance Protein(BCRP/ABCG2)による異物排泄の定量的解析 , 2008 .

[34]  John D. Allen,et al.  A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. , 2002, Cancer research.

[35]  Jiunn H. Lin,et al.  Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. , 2003, Advanced drug delivery reviews.